Results 131 to 140 of about 182,500 (270)

Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma

open access: yes, 2018
Pembrolizumab is a monoclonal antibody directed against PD-1 that is US FDA approved for treatment of advanced PD-L1 positive gastric and gastroesophageal junction adenocarcinoma in patients who have progressed on at least two prior lines of ...
Smita S Joshi   +2 more
core   +1 more source

Diabetes Increases Immunotherapy‐Related Toxicity but Not Efficacy in Metastatic Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT This multicenter retrospective study evaluated the impact of type 2 diabetes mellitus (DM) on clinical outcomes and immune‐related adverse events (irAEs) in 450 patients with metastatic non‐small cell lung cancer (NSCLC) treated with second‐line nivolumab at 17 centers between 2016 and 2024. Among these patients, 118 (26.2%) had DM.
Emre Çakır   +32 more
wiley   +1 more source

A pembrolizumab kezelés hatékonysága a recidiváló és metasztatikus méhnyakrák ellátásában

open access: yes
A pembrolizumab egy immunellenőrzőpont-gátló szer, amely a tumorsejt és a T-sejt interakciójában a programozott sejthalál ligand 1 (PD-L1) és receptora (PD-1) közötti kapcsolatot blokkolja és ezzel gátolja a daganattal szembeni immuntoleranciát.
Bodó, Krisztina
core  

Incidence and Predictors of Immune‐Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real‐World Cohort Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) frequently cause thyroid immune‐related adverse events (irAEs). Permanent hypothyroidism, the clinically most relevant phenotype, requires lifelong hormone replacement. We investigated its incidence, course, risk factors, and prognostic relevance under pembrolizumab.
Freya Koffka   +9 more
wiley   +1 more source

Early Cessation of Adjuvant Anti‐PD‐1 Therapy in Stage III and IV Melanoma

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT One year of adjuvant anti‐PD‐1 has improved disease‐free survival in Stage III melanoma. It is unknown whether shorter treatment duration affects outcomes. Real‐world data may help clarify this. In this retrospective observational study, patients with resected Stage III/IV melanoma receiving adjuvant anti‐PD‐1 in the Netherlands from 2018 to ...
Manja Bloem   +20 more
wiley   +1 more source

Activity of Low Dose Nivolumab in Patients With Advanced Squamous Cell Carcinomas and Other Cancers

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Immune checkpoint inhibitors such as anti–PD‐1 antibodies are essential in cancer therapy. Emerging data suggest that lower doses may be effective and more economical, though further evidence is needed. We conducted a retrospective study at Centre Léon Bérard to assess the efficacy and safety of low‐dose nivolumab (20 mg every 3 weeks) in ...
Thibault Gauduchon   +16 more
wiley   +1 more source

Descriptive Analysis of Epidemiology, Demographic Characteristics, and Survival of Dedifferentiated Liposarcoma in France

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Dedifferentiated liposarcoma (DDLPS) is a rare soft tissue sarcoma with limited real‐world epidemiologic data. This nationwide retrospective study describes the epidemiology, management, and outcomes of DDLPS in France using the NETSARC+ national sarcoma registry.
Julien Bollard   +23 more
wiley   +1 more source

Pembrolizumab Associated Autoimmune Diabetes Mellitus: Case Series [PDF]

open access: yes
The use of immune checkpoint inhibitors is increasing every day. With such frequent use, the side effects and management associated with these treatments are becoming difficult. One of rare side effects is autoimmune diabetes mellitus. In this review, we
Aslı GEÇGEL   +5 more
core   +1 more source

Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long‐Term Survival Outcomes

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Long‐term survival data for patients with locally advanced gastro‐esophageal adenocarcinoma (GEA) treated with neoadjuvant chemoimmunotherapy are lacking. We describe the long‐term disease‐free survival (DFS) and overall survival (OS) outcomes of such patients treated with a novel neoadjuvant chemoimmunotherapy regimen, aDCF (avelumab with ...
Thierry Alcindor   +8 more
wiley   +1 more source

Pembrolizumab treatment of prostate cancer [PDF]

open access: yes
In this case report, a 73-year-old male with metastatic prostate cancer is presented. After progression on available standard treatments, he was enrolled in a precision medicine program.
Hjelholt, Astrid Johanneson   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy